Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Open in API
Filings indexed 1,720 across all filing types
Latest filing 2024-08-01 Regulatory Filings
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-08-01 English
10-Q
Interim / Quarterly Report Q2 2024
2024-08-01 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 1, 2024, reporting the issuance of a press release announcing financial and operating results for the quarter ended June 30, 2024. The text explicitly states that the press release is being furnished as Exhibit 99.1 and is incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather serves as a current report to announce the release of quarterly financial results. According to the classification rules, such a filing is best categorized as an Earnings Release (ER) because it is the initial announcement of quarterly financial results, even though the full detailed report is not included here. The document length is 3622 characters, which is typical for an 8-K earnings release announcement. Therefore, the appropriate classification is ER with high confidence.
2024-08-01 English
PRIMARY DOCUMENT
Director's Dealing
2024-07-12 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC by Regeneron Pharmaceuticals, Inc. dated July 8, 2024. It reports preliminary financial results for the second quarter of 2024, specifically discussing an acquired in-process research and development charge and its expected impact on GAAP and non-GAAP net income per diluted share. The document explicitly states it is a "Current Report" pursuant to the Securities Exchange Act of 1934 and is not a full quarterly or annual report but a current report on material events. The content is typical of an earnings update or financial results announcement but is not a full earnings release with detailed financial statements. Given the nature of the Form 8-K and the content focusing on results of operations and financial condition, this fits best under the category of Earnings Release (ER). The document length (7860 characters) and content support it being more than a brief announcement but not a full interim report. Therefore, the classification is ER with high confidence.
2024-07-08 English
PRIMARY DOCUMENT
Director's Dealing
2024-07-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.